• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

    2/10/23 9:28:55 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email
    SC 13G/A 1 e618230_sc13ga-cp.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 1) *

     

    Catalyst Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    14888U101

    (CUSIP Number)

     

    December 31, 2022 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

     

    ----------

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

        

     

    CUSIP No. 14888U101 13G Page 2 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,884,448 (1)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,884,448 (1)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,884,448 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.65%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

       

    __________________ 

    (1) Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

     

     

    CUSIP No. 14888U101 13G Page 3 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,884,448 (2) 

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,884,448 (2)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,884,448 (2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.65%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

      

    __________________

    (2) Comprised of shares of common stock held by Deerfield Partners, L.P. of which Deerfield Management Company, L.P. is the investment advisor.

     

     

    CUSIP No. 14888U101 13G Page 4 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,884,448

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,884,448

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,884,448

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.65%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

      

     

    CUSIP No. 14888U101 13G Page 5 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,884,448 (3)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,884,448 (3)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,884,448 (3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.65%

    12.

    TYPE OF REPORTING PERSON*

     

    IN

      

    __________________

    (3) Comprised of shares of common stock held by Deerfield Partners, L.P.

     

     

    CUSIP No. 14888U101 13G Page 6 of 9

     

    Item 1(a). Name of Issuer:
       
     

    Catalyst Pharmaceuticals, Inc.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    355 Alhambra Circle, Suite 801

    Coral Gables, Florida, 33134

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen 

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock

       
    Item 2(e). CUSIP Number:
       
     

    14888U101

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

         
    (g) ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

      

     

    CUSIP No. 14888U101 13G Page 7 of 9

      

         

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

         
    (i) ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

         
    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. - 5,884,448 shares

    Deerfield Management Company, L.P. - 5,884,448 shares

    Deerfield Partners, L.P. - 5,884,448 shares

    James E. Flynn – 5,884,448 shares 

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 5.65%

    Deerfield Management Company, L.P. – 5.65%

    Deerfield Partners, L.P. – 5.65%

    James E. Flynn – 5.65% 

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 5,884,448

    Deerfield Management Company, L.P. - 5,884,448

    Deerfield Partners, L.P. - 5,884,448

    James E. Flynn – 5,884,448

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 5,884,448

    Deerfield Management Company, L.P. - 5,884,448

    Deerfield Partners, L.P. - 5,884,448

    James E. Flynn – 5,884,448

      

    **See footnotes on cover pages which are incorporated by reference herein.

      

     

    CUSIP No. 14888U101 13G Page 8 of 9

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☐.

       
       
       
    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. 

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8.

    Identification and Classification of Members of the Group. 

       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

     

     

    CUSIP No. 14888U101 13G Page 9 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: February 10, 2023

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.

     

    Exhibit B. Item 8 Statement.

     

    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Catalyst Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

     

     

    Get the next $CPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    Financials

    Live finance-specific insights

    See more
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb

      2/26/25 4:13:25 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

      CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. Presentation Details:Date: Wednesday, May 14, 2025Time: 8:00 am PTWebcast Link The webcast will be ava

      4/30/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CPRX
    SEC Filings

    See more
    • Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

      Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

      2/4/25 7:01:07 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Catalyst Pharma with a new price target

      Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

      11/18/24 8:40:25 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Catalyst Pharma with a new price target

      Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

      3/14/24 7:36:28 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      5/30/25 4:04:22 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      5/23/25 4:30:14 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      5/14/25 10:45:34 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

      CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the

      10/8/24 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

      Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Mr. Kalb will report directly to the Company's Chief Executive Officer and will serve as a member of the Company's executive leadership team. Mr. Kalb's distinguished career in

      12/4/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

      CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Richard J. Daly as its new Chief Executive Officer ("CEO") effective January 1, 2024. Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst. In order to facilitate an orderly transition, Patrick J. McEnany, Founder, Chairman, and CEO, will retire from the CEO position effective December 31, 2023, and at that time will contin

      10/19/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      11/14/24 9:55:56 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/18/24 3:31:27 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/17/24 12:14:52 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Med. & Reg. Officer Ingenito Gary exercised 244,000 shares at a strike of $3.64 and sold $5,775,720 worth of shares (244,000 units at $23.67) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      5/15/25 5:00:41 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Med. & Reg. Officer Ingenito Gary exercised 225,000 shares at a strike of $2.24 and sold $4,894,610 worth of shares (225,000 units at $21.75) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/7/25 5:00:21 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Compliance/Legal Officer Elsbernd Brian exercised 62,525 shares at a strike of $2.24 and sold $1,446,933 worth of shares (62,975 units at $22.98) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/5/25 5:00:39 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care